Quick Answer
ABVC BIOPHARMA, INC. reported Operating Income of -$7.15 million for fiscal year 2025.
ABVC BIOPHARMA, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.15M | -52.0% |
| 2024 | -$4.71M | +30.5% |
| 2023 | -$6.77M | +55.2% |
| 2022 | -$15.11M | -29.1% |
| 2021 | -$11.71M | -37.6% |
| 2020 | -$8.51M | -145.9% |
| 2019 | -$3.46M | -24.2% |
| 2018 | -$2.78M | +32.7% |
| 2017 | -$4.14M | -3.6% |
| 2017 | -$4.00M | +63.7% |
| 2016 | -$11.00M | -6104.1% |
| 2013 | -$177.3K | +84.5% |
| 2012 | -$1.14M | +39.5% |
| 2011 | -$1.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.17M | -286.5% | +49.1% |
| June 30, 2025 | -$2.29M | -166.8% | -231.2% |
| March 31, 2025 | -$693.0K | +75.6% | -129.2% |
| September 30, 2024 | -$302.3K | +86.0% | +64.9% |
| June 30, 2024 | -$860.1K | +60.8% | +69.7% |
| March 31, 2024 | -$2.84M | -48.9% | -31.7% |
| September 30, 2023 | -$2.15M | +42.0% | +1.8% |
| June 30, 2023 | -$2.19M | -7.2% | -15.1% |
- ABVC BIOPHARMA, INC. showed a decrease of -52.0% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, ABVC BIOPHARMA, INC.’s operating income has declined by 278.8% (from -$1.89 million to -$7.15 million).
- The most recent figure is from ABVC BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: